Year All20242023202220212020201920182017201620152014 Nov 09, 2022 Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results Oct 03, 2022 Soleno Therapeutics Announces Initiation of Randomized Withdrawal Study of DCCR for the Treatment of Prader-Willi Syndrome Sep 06, 2022 Soleno Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference Aug 10, 2022 Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results Jul 20, 2022 Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome Jul 11, 2022 Soleno Therapeutics Announces Presentation of DCCR Data at the 11th International Prader-Willi Syndrome Organisation Conference Jun 13, 2022 Soleno Therapeutics Presents Long Term Data for DCCR Showing Metabolic and Body Composition Improvements in Patients with PWS Jun 07, 2022 Soleno Therapeutics Announces Presentations at ENDO 2022 May 19, 2022 Soleno Therapeutics Announces Presentations at the 2022 European Congress of Endocrinology May 17, 2022 Soleno Therapeutics to Participate in the H.C. Wainwright Global Investment Conference
Nov 09, 2022 Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results
Oct 03, 2022 Soleno Therapeutics Announces Initiation of Randomized Withdrawal Study of DCCR for the Treatment of Prader-Willi Syndrome
Sep 06, 2022 Soleno Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
Aug 10, 2022 Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results
Jul 20, 2022 Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome
Jul 11, 2022 Soleno Therapeutics Announces Presentation of DCCR Data at the 11th International Prader-Willi Syndrome Organisation Conference
Jun 13, 2022 Soleno Therapeutics Presents Long Term Data for DCCR Showing Metabolic and Body Composition Improvements in Patients with PWS
May 19, 2022 Soleno Therapeutics Announces Presentations at the 2022 European Congress of Endocrinology